Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04857684 · ClinicalTrials.gov registry record · Early Phase 1

SBRT + Atezolizumab + Bevacizumab in Resectable HCC

A Early Phase 1 study of Hepatocellular Carcinoma and Resectable Hepatocellular Carcinoma, sponsored by Massachusetts General Hospital.

Active
Registry status
Early Phase 1
Development phase
20
Enrollment target
1
Study location

NCT04857684: Active Early Phase 1 study of Hepatocellular Carcinoma and Resectable Hepatocellular Carcinoma, sponsored by Massachusetts General Hospital.

NCT04857684 is a Early Phase 1 study of Hepatocellular Carcinoma and Resectable Hepatocellular Carcinoma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04857684, a Early Phase 1 study of Hepatocellular Carcinoma and Resectable Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This study is evaluating the safety and tolerability of neoadjuvant stereotactic body radiation therapy (SBRT) with atezolizumab and bevacizumab for treating resectable hepatocellular carcinoma. This study involves the following study interventions: * Atezolizumab * Bevacizumab * Stereotactic Beam Radiation Therapy (SBRT) * Surgery

Primary Outcome

Assessed by CTCAE v5.0

Interventions

  • DRUG Bevacizumab
  • DRUG Atezolizumab
  • RADIATION Stereotactic Beam Radiation Therapy (SBRT)

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2021-06-18
Est. Completion 2027-04-29
Phase Early Phase 1
Massachusetts General Hospital

2,032 total trials

What the registry record for NCT04857684 still lists

NCT04857684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower).

The record links to 2 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.

NCT04857684 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04857684 about?

NCT04857684 is a clinical study titled "SBRT + Atezolizumab + Bevacizumab in Resectable HCC". This study is evaluating the safety and tolerability of neoadjuvant stereotactic body radiation therapy (SBRT) with atezolizumab and bevacizumab for treating resectable hepatocellular carcinoma. This study involves the following study interventions: * Atezolizumab * Bevacizumab * Stereotactic Beam...

What is the current status of trial NCT04857684?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2021-06-18. Estimated completion is 2027-04-29.

What conditions does trial NCT04857684 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma.

What interventions are being tested in trial NCT04857684?

The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Stereotactic Beam Radiation Therapy (SBRT) (RADIATION).

Who is sponsoring clinical trial NCT04857684?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04857684 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04857684's enrollment target sits among peer trials

20 123rd of 145 higher than 16 of 145 other Hepatocellular Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04857684, the US trial registry maintained by the National Library of Medicine. NCT04857684 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.